• Mashup Score: 4
    Is This the End of Cancer Research as We Know It? - 10 hour(s) ago

    Ongoing efforts to rein in government spending have been described as a “chainsaw for bureaucracy.” It’s an apt metaphor for the haphazard budget cuts that many federal agencies are still experiencin…

    Source: ascopost.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Cancer research is evolving—and fast. This ASCO Post article asks a bold question: Are we witnessing the end of cancer research as we know it? 🔗 https://t.co/teylIbFPIw #ASCO2025 #OncologyLeadership https://t.co/D4vqicZkw6

  • Mashup Score: 9
    Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer - 2 day(s) ago

    The French phase II PANACHE01-PRODIGE48 trial investigated the feasibility and efficacy of neoadjuvant mFOLFIRINOX and FOLFOX in patients with resectable pancreatic adenocarcinoma.

    Source: ascopost.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      New insights from #ASCO2025: Neoadjuvant chemo shows promise for resectable pancreatic cancer—could this redefine standard of care? 🔗 https://t.co/HbOaJfcnHC #PancreaticCancer #OncologyResearch https://t.co/XS5mJTPYdU

  • Mashup Score: 8
    CAP Issues New and Updated Cancer Protocols - 3 day(s) ago

    New protocols for endocrine tumors and updated existing protocols for breast cancer diagnoses are now available from the College of American Pathologists (CAP).

    Source: ascopost.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      🚨 Just released: CAP updates its cancer reporting protocols — a must-read for oncologists ahead of #ASCO25. 🧠 Precision starts with pathology. Stay ahead of the curve. 🔗 https://t.co/keOs1EIlBn #Oncology #CancerResearch #CAP #Pathology #ClinicalOncology #PrecisionMedicine https://t.co/VaTmZfC73U

  • Mashup Score: 4
    Advanced Esophageal Cancer: NOTCH1 Mutation and Efficacy of Tislelizumab - 6 day(s) ago

    “Although multiple agents targeting PD-1 have been approved as second-line treatment for esophageal squamous cell carcinoma, only a fraction of patients derive long-term survival. Hence, reliable pred…

    Source: ascopost.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      NOTCH1 mutations may influence immunotherapy outcomes in advanced esophageal cancer. In RATIONALE-302, patients with NOTCH1 mutations saw improved OS with tislelizumab vs chemo. Full summary via @ASCOPost: https://t.co/r9nssMlbRW #OncologyResearch #ASCO25 https://t.co/ST7861KYqb

  • Mashup Score: 3
    Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer - 7 day(s) ago

    The French phase II PANACHE01-PRODIGE48 trial investigated the feasibility and efficacy of neoadjuvant mFOLFIRINOX and FOLFOX in patients with resectable pancreatic adenocarcinoma.

    Source: ascopost.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      New data on neoadjuvant chemotherapy in resectable pancreatic cancer raises key questions about treatment sequencing. Now in The ASCO Post: https://t.co/zWjd5kkZgp #ASCO25 #OncologyResearch https://t.co/SO97wkGNbO

  • Mashup Score: 9
    Triple-Negative Breast Cancer: Neoadjuvant Nivolumab Initiation - 8 day(s) ago

    The phase II Neo-N trial investigated the activity of two differing schedules of neoadjuvant nivolumab initiation—lead-in or concurrent—with 12 weeks of carboplatin and paclitaxel in patients with ear…

    Source: ascopost.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Does the timing of neoadjuvant nivolumab initiation affect outcomes in early-stage triple-negative breast cancer? A phase II study led by @LoiSher explores this critical question. Read more: https://t.co/ZnMrS9wpK9 #TripleNegativeBreastCancer #Immunotherapy https://t.co/70FCZA4Fps

  • Mashup Score: 7
    Low-Dose vs Regular-Dose Apixaban for Prevention of VTE Recurrence in Patients With Cancer - 9 day(s) ago

    Patients with active cancer who developed venous thromboembolism (VTE) and were treated with anticoagulants for at least 6 months, followed by an additional 12 months of low-dose apixaban, experienced…

    Source: www.ascopost.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      New data alert for oncologists: Is low-dose apixaban just as effective as standard dosing for preventing VTE recurrence in cancer patients? This study could shift clinical practice. Read more 👉 https://t.co/jiKeRUEogW #Oncology #ASCO #CancerResearch #VTE #Apixaban #HemOnc https://t.co/Gs9e5Tv0oj

  • Mashup Score: 2
    Liquid Biopsies Could Help Guide Colorectal Cancer Treatment - 13 day(s) ago

    The use of a circulating tumor DNA liquid biopsy to guide colorectal cancer treatment in the adjuvant setting may not compromise outcomes despite allowing many patients to avoid chemotherapy.

    Source: ascopost.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Liquid biopsies may offer new insights for guiding colorectal cancer treatment, according to The ASCO Post. ctDNA continues to show promise in personalizing care. Read more: https://t.co/ZCpZXFhk4a #Oncology #ASCO25 https://t.co/giPE3mT40F

Load More